Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract.
暂无分享,去创建一个
Jason R. Baker | G. Amidon | R. Lionberger | W. Hasler | Mark J. Koenigsknecht | Xinyuan Zhang | Ann F. Fioritto | Duxin Sun | Y. Tsume | Bo Wen | A. Yu | Ruijuan Luo | Siwei Li | M. Bly | Ying Wang
[1] Patrick Martin,et al. Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis , 2016, Drug design, development and therapy.
[2] D. V. van Langenberg,et al. Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal? , 2015, World journal of gastrointestinal pharmacology and therapeutics.
[3] H. Isomoto,et al. Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis , 2014, Medical science monitor : international medical journal of experimental and clinical research.
[4] K. Nanda,et al. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum] , 2013, Clinical pharmacology : advances and applications.
[5] A. Moss,et al. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine , 2012, Clinical pharmacology : advances and applications.
[6] P. L. McCormack,et al. MMX® Mesalazine , 2011, Drugs.
[7] B. Feagan,et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2012, The Cochrane database of systematic reviews.
[8] P. Moayyedi,et al. Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.
[9] Svetlana Lyapustina,et al. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. , 2010, Journal of aerosol medicine and pulmonary drug delivery.
[10] T. Hibi,et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: A double-blind, randomized study , 2010, Inflammatory bowel diseases.
[11] S. Hanauer,et al. Aminosalicylates for induction of remission or response in Crohn's disease. , 2010, The Cochrane database of systematic reviews.
[12] M. Campieri,et al. Clinical trial: ulcerative colitis maintenance treatment with 5‐ASA: a 1‐year, randomized multicentre study comparing MMX® with Asacol® , 2009, Alimentary pharmacology & therapeutics.
[13] Robert A. Lionberger,et al. FDA Critical Path Initiatives: Opportunities for Generic Drug Development , 2008, The AAPS Journal.
[14] A. Moss,et al. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. , 2008, Drugs.
[15] M. Kamm,et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.
[16] M. Kamm,et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] O. Dewit,et al. Once daily MMX mesalazine for the treatment of mild‐to‐moderate ulcerative colitis: a phase II, dose‐ranging study , 2006, Alimentary pharmacology & therapeutics.
[18] O. Paoluzi,et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study , 2005, Alimentary pharmacology & therapeutics.
[19] S. Hanauer,et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis , 1995, Digestive Diseases and Sciences.
[20] S. Weir,et al. Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man , 2004, European Journal of Clinical Pharmacology.
[21] S. Hanauer,et al. The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.
[22] J. Macdonald,et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2003, The Cochrane database of systematic reviews.
[23] I. Wilding. Bioequivalence Testing for Locally Acting Gastrointestinal Products: What Role for Gamma Scintigraphy? , 2002, Journal of clinical pharmacology.
[24] D. Podolsky,et al. Inflammatory bowel disease. , 2002, The New England journal of medicine.
[25] S. Hanauer,et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. , 1995, Digestive diseases and sciences.
[26] S. Hanauer,et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.
[27] S. Lo,et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. , 1991, Annals of internal medicine.
[28] S. Hansen,et al. Topical and systemic availability of 5‐amino‐salicylate: comparisons of three controlled release preparations in man , 1990, Alimentary pharmacology & therapeutics.
[29] S. Hansen,et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. , 1982, Gastroenterology.
[30] M. Peppercorn,et al. Distribution studies of salicylazosulfapyridine and its metabolites. , 1973, Gastroenterology.
[31] H. Schröder,et al. Absorption, metabolism, and excretion of salicylazosulfapyridine in man , 1972, Clinical pharmacology and therapeutics.